GRAd-COV2
From Wikipedia, the free encyclopedia
Jump to navigation
Jump to search
Vaccine candidate against COVID-19
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Viral vector |
Clinical data | |
Routes of administration | Intramuscular |
Part of a series on the |
COVID-19 pandemic |
---|
|
By continent
By conveyance |
International response |
Socio-economic
By industry |
COVID-19 portal |
GRAd-COV2 is a COVID-19 vaccine candidate developed by ReiThera and Lazzaro Spallanzani National Institute for Infectious Diseases.[1][2]
References[edit]
- ^ "GRAd-COV2 Vaccine Against COVID-19". ClinicalTrials.gov. United States National Library of Medicine. 7 January 2021. NCT04528641.
- ^ "ReiThera Announces its GRAd-COV2 COVID-19 Vaccine Candidate is Well Tolerated and Induces Clear Immune Responses in Healthy Subjects Aged 18–55 Years". ReiThera Srl. Yahoo! Finance. 24 November 2020. Retrieved 12 January 2021.
External links[edit]
Scholia has a profile for GRAd-COV2 (Q98945351). |
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|
This article about the COVID-19 pandemic is a stub. You can help Wikipedia by expanding it. |
This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |
Hidden categories:
- Articles with short description
- Short description is different from Wikidata
- Use dmy dates from April 2021
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a vaccine
- All stub articles